Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 10:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,500 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Progerinin in Healthy Volunteers

NCT04512963
Conditions
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Interventions
Progerinin, Placebo
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Conditions
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia, Non Fanconi DNA-DSB Repair Disorder, Hoyeraal-Hreidarsson Syndrome, Dyskeratosis Congenita, Telomere Biology Disorder, Short Telomere Syndrome
Interventions
Alemtuzumab, Fludarabine, Melphalan, Low Dose Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Months to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Traumatic Nerve Injury
Interventions
Hollow tube nerve conduit, synthetic or biosynthetic, Processed Human Nerve Tissue
Device · Other
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 1 more
Conditions
Traumatic Femur Fracture
Interventions
Ropivicaine, Epinephrine
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Prostate Adenocarcinoma
Interventions
Niraparib Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Tendon Injuries, Tendinopathy
Interventions
NuShield
Other
Lead sponsor
NuTech Medical, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Aurora, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Video-based Collaborative Learning to Improve Ventral Hernia Repair

NCT04173884
Conditions
Ventral Hernia
Interventions
Coaching, Constructive Feedback
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 1 Interventional Results available

Phase Ib of L-NMMA and Pembrolizumab

NCT03236935
Conditions
Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma Bladder, DNA Repair-Deficiency Disorders
Interventions
L-NMMA, Pembrolizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Ataxia Telangiectasia
Interventions
Antisense oligonucleotide targeting the ATM gene
Drug
Lead sponsor
Timothy Yu
Other
Eligibility
0 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Rib Fracture
Interventions
Resection with or without plate fixation
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Recruiting No phase listed Observational

TDAP in Burn Patients (Group 2)

NCT07223684
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Conditions
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Interventions
HRO761, pembrolizumab, irinotecan
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Conditions
Fanconi Anemia
Interventions
AMD3100, AmCell CliniMACs
Drug · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair

NCT02162810
Conditions
Hypospadias
Interventions
Prednisolone, placebo-controlled
Drug
Lead sponsor
Francis Schneck
Other
Eligibility
3 Months to 22 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Juxtarenal Abdominal Aortic Aneurysm
Interventions
Endovascular Aneurysm Repair with Physician Modified Endograft
Device
Lead sponsor
Cali Johnson
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Hernia, Inguinal
Interventions
Robotic-assisted inguinal hernia repair
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Newport News, Virginia
Conditions
Heart Diseases, Heart Transplantation
Interventions
Tacrolimus, Cyclosporine, Mycophenolate mofetil, Methylprednisolone, Prednisone
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Conditions
Mitral Regurgitation Functional, Mitral Valve Disease, Cardiovascular Diseases
Interventions
Millipede Transcatheter Annuloplasty Ring System (Millipede System)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • The Bronx, New York
Conditions
Functional Mitral Regurgitation, Heart Failure
Interventions
Mitral Loop Cerclage Annuloplasty
Device
Lead sponsor
Tau-MEDICAL Co., Ltd.
Industry
Eligibility
20 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Procedural Anxiety
Interventions
Intranasal midazolam
Drug
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 7 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Postoperative Pain
Interventions
Liposomal bupivacaine, Placebo - injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Leg Ulcer, Veins, Varicose, Venous Ulcer, Reflux, Venous Reflux, Venous Leg Ulcer, Varicose Veins, Varicose Ulcer, Varicose Veins Leg
Interventions
Polidocanol Endovenous Microfoam (PEM)
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Colorectal Adenocarcinoma
Interventions
VVD-133214, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more